News
We're investing in research into inflammation that could help develop drugs that slow the progression of Parkinson's, something no current medication can do.
The first participant has been recruited to a pioneering clinical trial which is testing a new drug called NLX-112 to investigate its potential for people with Parkinson's.
UCB, a global pharmaceutical company, has joined forces with Parkinson's UK, and the Parkinson's Foundation in the US, to establish a Patient Engagement Council for Parkinson's Research.
We've launched a new report, Nobody really knows us – the state of health and social care for people with Parkinson's-related dementia.
We've developed an interactive communications toolkit to help researchers in all areas of health research to keep in touch with their participants. It is supported by the Health Research Authority (HRA) as part of the Make It Public strategy.
At our Parkinson's UK AGM on Saturday 16 October Sally Bromley and Samantha Aylieff were elected as new trustees to the Board.
Next has released a new exclusive range in collaboration with internationally-renowned artist Alex Echo, who was diagnosed with Parkinson's in early 2020.
Not enough people understand what it's like to live with Parkinson's. Together, we can change that.
We've invested a further £490,000 to support the development of drugs to protect mitochondria and treat Parkinson's.
Results show that atomoxetine, a drug used to treat attention deficit hyperactivity disorder (ADHD), could improve thinking and impulsiveness in Parkinson's.